| 前收市價 | 0.1500 |
| 開市 | 0.1100 |
| 買盤 | 0.0900 |
| 賣出價 | 0.1100 |
| 拍板 | 1.50 |
| 到期日 | 2026-01-16 |
| 今日波幅 | 0.1100 - 0.1200 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 989 |
BenzingaNASDAQ Cannabis Titan, Aurora, Could Boost 31% Sales Surge With This New CBD Lozenge Partnership
Aurora Cannabis Inc. (NASDAQ:ACB) has partnered with Vectura Fertin Pharma, Inc. to launch a CBD lozenge in the form of a dissolvable tablet that delivers the precise dose of cannabidiol (CBD). The new product is expected to enhance patient care by providing an alternative consumption method without psychoactive effects. The partnership leverages Aurora’s extensive medical cannabis patient platform, said Aurora CEO Miguel Martin, who added that the company intends to broaden Canadian healthcare
Motley FoolPrediction: Aurora Cannabis Will Be Worth More Than Canopy Growth in 5 Years
While these stocks are both highly risky investments, Aurora Cannabis may be in a better position right now than its longtime rival.
BenzingaAurora Cannabis Dominates 30% Of Canada's Medical Marijuana Exports: Will Its Bold International Expansion Pay Off?
Aurora Cannabis (NASDAQ:ACB) saw its international sales for the first half of 2024 reach C$39.3 million ($28.9 million), reflecting a 31% year-over-year increase. This growth includes the full acquisition of MedReleaf Australia in February 2024, which contributed significantly to the sales boost. A Wednesday report by Pablo Zuanic of Zuanic & Associates provides a detailed analysis of the company’s recent activities and financial standing. International Sales And Market Position Aurora remains
